(486 days)
Not Found
No
The device description details a standard immunochemical assay with spectrophotometric measurement and a stored calibration curve for determining concentration. There is no mention of AI or ML in the device description, intended use, or performance studies.
No
This device is for in vitro diagnostic use, meaning it measures substances in human samples to provide information for diagnosis, but it does not directly treat or prevent conditions.
Yes
The "Intended Use / Indications for Use" section explicitly states "For in vitro diagnostic use only" and that the reagent is used "to quantitatively measure C-reactive protein (CRP) in human serum and plasma" to "evaluate conditions thought to be associated with inflammation." These are characteristics of a diagnostic device.
No
The device is an in vitro diagnostic reagent kit used with specific hardware systems (VITROS Chemistry Systems) to perform a quantitative measurement. It is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "For in vitro diagnostic use only."
- Nature of the Test: The device measures C-reactive protein (CRP) in human serum and plasma. This is a laboratory test performed on biological samples outside of the body, which is the definition of an in vitro diagnostic test.
- Purpose: The test is used to "quantitatively measure C-reactive protein (CRP) in human serum and plasma" and "to evaluate conditions thought to be associated with inflammation in otherwise healthy individuals." This indicates its use in diagnosing or monitoring a medical condition.
- Device Description: The description details a laboratory assay using reagents, calibrators, and a chemistry system to measure a substance in a biological sample.
All of these points confirm that this device is an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
VITROS Chemistry Products hsCRP Reagent:
For in vitro diagnostic use only. Rx Only.
VITROS Chemistry Products hsCRP Reagent is used on the VITROS 5,1 FS Chemistry System, the VITROS 4600 Chemistry System and the VITROS 5600 Integrated System to quantitatively measure C-reactive protein (CRP) in human serum and plasma. CRP is used to evaluate conditions thought to be associated with inflammation in otherwise healthy individuals.
Product codes (comma separated list FDA assigned to the subject device)
DCK
Device Description
The quantitative measurement of C-reactive protein (CRP) is performed using the VITROS Chemistry Products hsCRP Reagent in conjunction with the VITROS Chemistry Products Calibrator Kit 17 and VITROS Chemistry Products FS Calibrator 1 on the VITROS 5,1 FS/4600 Chemistry System and the VITROS 5600 Integrated System. The VITROS Chemistry Products hsCRP Reagent is a dual chambered package containing ready-to-use liquid reagents. Samples, calibrators and controls are mixed with Reagent 1 containing a buffer. Addition of anti-CRP antibodies coupled to latex microparticles (Reagent 2) produces an immunochemical reaction yielding CRP antigen/antibody complexes. The turbidity is measured spectrophotometrically at 660 nm. Once a calibration has been performed for each reagent lot, the CRP concentration in each unknown sample can be determined using the stored calibration curve and the measured absorbance obtained in the assay of the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Method Comparison:
CLSI Protocol EP09-A3, Measurement Procedure Comparison and Bias Estimation Using Patient Samples. Approved Guideline - Third Edition. A total of 119 human serum samples were tested. The 119 samples were measured with VITROS hsCRP assay on the VITROS 5600, 4600, and 5,1 Systems and a predicate method, Diazyme hsCRP assay on the Hitachi 917 Systems. Of the 119 samples tested 113 were within the measuring range of both the VITROS hsCRP assay (0.34-15.0 mg/L) and the Diazyme hsCRP assay (0.20 - 20.0 mg/L).
- VITROS 5600 Integrated System = 1.02 x Diazyme hsCRP Method + 0.26
- VITROS 4600 Integrated System = 1.02 x VITROS 5600 System + 0.01
- VITROS 5,1 FS System = 1.07 x VITROS 5600 System + 0.11
The data demonstrates acceptable correlation was obtained between the VITROS hsCRP assay (traceable to European Reference Material ERM-DA474/IFCC) versus the predicate method (traceable to European Reference Material ERM-DA472/IFCC) and between VITROS Systems.
Precision:
CLSI Protocol EP05-A3, Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition, October 2014. Five replicates of three human serum sample pools were run once per day for five days using two hsCRP Reagent lots and two Calibrator Kit 17 lots across three VITROS Chemistry Systems.
Results provided in a table.
Expected values/Reference range:
CLSI EP28-A3 Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition; a 50% male and 50% female population was utilized. Reference value:
§ 866.5270 C-reactive protein immunological test system.
(a)
Identification. A C-reactive protein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the C-reactive protein in serum and other body fluids. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, arranged in a cascading manner. The profiles are black and are meant to represent the department's focus on people and health. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the image.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 July 14, 2017
ORTHO-CLINICAL DIAGNOSTICS, INC. MARLENE HANNA, SENIOR MANAGER, REGULATORY AFFAIRS 100 INDIGO CREEK DRIVE ROCHESTER, NY 14626
Re: K160712
Trade/Device Name: VITROS Chemistry Products hsCRP Reagent Regulation Number: 21 CFR 866.5270 Regulation Name: C-reactive protein immunological test system Regulatory Class: II Product Code: DCK Dated: June 9, 2017 Received: June 12, 2017
Dear Marlene Hanna:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
K160712
Device Name VITROS Chemistry Products hsCRP Reagent
Indications for Use (Describe)
VITROS Chemistry Products hsCRP Reagent:
For in vitro diagnostic use only. Rx Only.
VITROS Chemistry Products hsCRP Reagent is used on the VITROS 5,1 FS Chemistry System, the VITROS 4600 Chemistry System and the VITROS 5600 Integrated System to quantitatively measure C-reactive protein (CRP) in human serum and plasma. CRP is used to evaluate conditions thought to be associated with inflammation in otherwise healthy individuals.
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary: K160712
| VITROS Chemistry Products hsCRP Reagent: A summary of 510(k) safety and effectiveness |
|---|
| information in accordance with the requirements of 21 CFR 807.92. |
| Submitter Information | |
|---|---|
| Name | Ortho-Clinical Diagnostics, Inc. |
| Address | 100 Indigo Creek Drive |
| Rochester, New York 14626 | |
| Phone number | 585-453-4041 |
| Fax number | 585-453-3368 |
| Establishment | |
| Registration | 1319681 |
| Name of contact person | Marlene Hanna |
| Date prepared | July 13, 2017 |
| Trade or proprietary | |
| name | VITROS Chemistry Products hsCRP Reagent |
| Common or usual name | C-reactive protein immunological test system |
| Classification name | Cardiac c-reactive protein, antigen, antiserum |
| Classification panel | Immunology |
| Regulation | 21 CFR 866.5270: C-Reactive Protein immunological test system |
| Classification: Class II | |
| Product Code(s) | DCK |
| Legally marketed | |
| device(s) to which | |
| equivalence is claimed | The Diazyme high sensitivity C-reactive protein (hsCRP) assay |
| (K103557) | |
| Device description | The quantitative measurement of C-reactive protein (CRP) is |
| performed using the VITROS Chemistry Products hsCRP Reagent in | |
| conjunction with the VITROS Chemistry Products Calibrator Kit 17 | |
| and VITROS Chemistry Products FS Calibrator 1 on the VITROS 5,1 | |
| FS/4600 Chemistry System and the VITROS 5600 Integrated | |
| System. The VITROS Chemistry Products hsCRP Reagent is a dual | |
| chambered package containing ready-to-use liquid reagents. Samples, | |
| calibrators and controls are mixed with Reagent 1 containing a | |
| buffer. Addition of anti-CRP antibodies coupled to latex | |
| microparticles (Reagent 2) produces an immunochemical reaction | |
| yielding CRP antigen/antibody complexes. The turbidity is measured | |
| spectrophotometrically at 660 nm. Once a calibration has been | |
| performed for each reagent lot, the CRP concentration in each | |
| unknown sample can be determined using the stored calibration curve | |
| and the measured absorbance obtained in the assay of the sample. |
4
| Intended Use | VITROS hsCRP Reagent: |
|---|---|
| For in vitro diagnostic use only. Rx ONLY. | |
| VITROS Chemistry Products hsCRP Reagent is used on the | |
| VITROS 5,1 FS Chemistry System, the VITROS 4600 | |
| Chemistry System and the VITROS 5600 Integrated System to | |
| quantitatively measure C-reactive protein (CRP) in human serum and | |
| plasma. CRP is used to evaluate conditions thought to be associated | |
| with inflammation in otherwise healthy individuals. |
Comparison with Predicate Devices:
Table 1: VITROS Chemistry Products hsCRP Reagent
| Characteristic | Predicate (Diazyme high sensitivity
C-Reactive Protein: K103557) | New Device (VITROS hsCRP
Reagent (Modified)) |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | For in vitro diagnostic use only. Rx
ONLY.
The Diazyme high sensitivity C-
reactive protein (hsCRP) assay is for
the in vitro quantitative determination
of C-reactive protein (CRP) in human
serum and plasma on automated
clinical chemistry analyzers.
Measurement of CRP is of use for the
detection and evaluation of
inflammatory disorders and
associated diseases, infection and
tissue injury. | For in vitro diagnostic use only. Rx
ONLY.
VITROS Chemistry Products hsCRP
Reagent is used
to quantitatively measure C-reactive
protein (CRP) in human serum and
plasma. CRP is used to evaluate
conditions thought to be associated with
inflammation in otherwise healthy
individuals. |
| Basic Principle | Latex enhanced immunoturbidimetric
assay | Two-point rate, 2mmune-turbidimetric
assay |
| Sample type | Serum, plasma | Serum, plasma |
| Assay Range Serum,
Plasma | 0.20 to 20.0 mg/L | 0.34 to 15.00 mg/L |
Performance Summary:
Substantial Equivalence was demonstrated by testing several performance characteristics including method comparison, precision, reference interval, linearity and detection limit.
Method Comparison:
Method Comparison testing followed CLSI Protocol EP09-A3, Measurement Procedure Comparison and Bias Estimation Using Patient Samples. Approved Guideline - Third Edition. A total of 119 human serum samples were tested. The 119 samples were measured with VITROS hsCRP assay on the VITROS 5600, 4600, and 5,1 Systems and a predicate method, Diazyme
5
hsCRP assay on the Hitachi 917 Systems. Of the 119 samples tested 113 were within the measuring range of both the VITROS hsCRP assay (0.34-15.0 mg/L) and the Diazyme hsCRP assay (0.20 - 20.0 mg/L).
The relationship between the VITROS hsCRP method and the Predicate method (Diazyme hsCRP) based on data from 113 samples on the VITROS 5600 Chemistry System is as follows:
VITROS 5600 Integrated System = 1.02 x Diazyme hsCRP Method + 0.26
The relationship between the VITROS hsCRP method on the VITROS 4600 System and the VITROS 5600 System based on data from 110 samples is as follows;
VITROS 4600 Integrated System = 1.02 x VITROS 5600 System + 0.01
The relationship between the VITROS hsCRP method on the VITROS 5.1 FS System and the VITROS 5600 System based on data from 109 samples is as follows;
VITROS 5,1 FS System = 1.07 x VITROS 5600 System + 0.11
The data demonstrates acceptable correlation was obtained between the VITROS hsCRP assay (traceable to European Reference Material ERM®-DA474/IFCC) versus the predicate method (traceable to European Reference Material ERM®-DA472/IFCC) and between VITROS Systems.
Precision:
The method was based upon the Clinical and Laboratory Standards Institute (CLSI) Protocol EP05-A3, Evaluation of Precision of Ouantitative Measurement Procedures; Approved Guideline-Third Edition, October 2014. Five replicates of three human serum sample pools were run once per day for five days using two hsCRP Reagent lots and two Calibrator Kit 17 lots across three VITROS Chemistry Systems.
Testing was conducted using VITROS Chemistry Products hsCRP Reagent calibrated with VITROS Chemistry Products Calibrator Kit 17 and VITROS Chemistry Products FS Calibrator 1 traceable to ERM-DA474. Precision study results for the VITROS hsCRP assay are listed in table 1.
6
Table 1: Precision study
| | Reagent
Mean | | Within-run | | Between-run | | Total | |
|-----------------|-----------------|-------|------------|------|-------------|------|-------|------|
| Analyzer | Lot | Conc. | SD | %CV | SD | %CV | SD | %CV |
| 5,1 FS
PM675 | 35-5544 | 0.96 | 0.067 | 6.96 | 0.000 | 0.00 | 0.067 | 6.96 |
| | | 9.65 | 0.104 | 1.08 | 0.080 | 0.83 | 0.132 | 1.37 |
| | | 13.41 | 0.156 | 1.16 | 0.081 | 0.60 | 0.176 | 1.31 |
| | 36-5726 | 1.02 | 0.060 | 5.90 | 0.024 | 2.36 | 0.065 | 6.39 |
| | | 9.89 | 0.151 | 1.53 | 0.124 | 1.25 | 0.196 | 1.98 |
| | | 13.86 | 0.266 | 1.92 | 0.134 | 0.97 | 0.298 | 2.15 |
| 4600
PM102 | 35-5544 | 0.97 | 0.063 | 6.53 | 0.000 | 0.00 | 0.063 | 6.53 |
| | | 9.52 | 0.188 | 1.97 | 0.000 | 0.00 | 0.188 | 1.97 |
| | | 13.12 | 0.269 | 2.05 | 0.067 | 0.51 | 0.277 | 2.11 |
| | 36-5726 | 1.01 | 0.047 | 4.66 | 0.021 | 2.08 | 0.052 | 5.16 |
| | | 9.79 | 0.253 | 2.58 | 0.144 | 1.47 | 0.291 | 2.97 |
| | | 13.64 | 0.400 | 2.93 | 0.078 | 0.57 | 0.408 | 2.99 |
| 5600
PM109 | 35-5544 | 0.92 | 0.053 | 5.77 | 0.000 | 0.00 | 0.053 | 5.77 |
| | | 9.34 | 0.081 | 0.87 | 0.081 | 0.87 | 0.115 | 1.23 |
| | | 12.78 | 0.126 | 0.99 | 0.110 | 0.86 | 0.167 | 1.31 |
| | 36-5726 | 1.00 | 0.054 | 5.40 | 0.000 | 0.00 | 0.054 | 5.40 |
| | | 9.54 | 0.113 | 1.18 | 0.121 | 1.27 | 0.165 | 1.73 |
| | | 13.26 | 0.278 | 2.10 | 0.148 | 1.12 | 0.315 | 2.38 |
Expected values/Reference range:
The reference interval was verified according to CLSI EP28-A3 Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition; a 50% male and 50% female population was utilized. Reference intervals may differ for each population studied and therefore each laboratory should confirm the validity of these intervals for the population it serves. Increases in CRP values are non-specific and should be interpreted together with a complete clinical history. Follow-up testing of patients with elevated CRP values should be performed.
| Conventional and SI Units (mg/L) |
|---|
| $ |